Ranbaxy, Statement on FDA Letters
GURGAON, India, September 17, 2008 /PRNewswire/ — In response to a U.S. Food and Drug Administration press release announcing warning letters and an Import Alert for Drugs issued to Ranbaxy Laboratories Ltd. regarding drug products produced in two Ranbaxy plants in India, the company issued the following statement:
“Ranbaxy is very disappointed in the action taken by the U.S. FDA. The company has responded to each concern the FDA has raised during the past two years and had thought that progress was being made. We are, however, pleased that the FDA’s testing and review led the agency to conclude that there is no reason to question the safety or effectiveness of Ranbaxy’s drugs. The company has just received the warning letters that FDA has issued and has not had the opportunity to review those concerns that FDA has determined are unresolved. Once it has had an opportunity to review the issues, the company looks forward to continuing to cooperate with FDA to resolve the remaining issues.”
According to the FDA announcement, the warning letters and Import Alert do not apply to Ranbaxy’s other facilities, including its three manufacturing facilities in the U.S.: Ohm Laboratories’ facilities in New Brunswick, NJ, North Brunswick, NJ, and Gloversville, NY, from which Ranbaxy delivers some 59 drug products to the U.S. healthcare system, including: Simvastatin, Acyclovir, Minocycline, Clindamycin, Lorazepam, Loratadine-D, Cetirizine, Acetaminophen Extended release tablets, Lisinopril and Zolpidem.
Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies,” resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.
Ramesh L. Adige
Executive Director — Corporate Affairs and Global Corporate Communications
Ranbaxy Laboratories Ltd.
Plot 90, Sector 32, Gurgaon
Haryana122001, India
Tel: 91-124-4135000
e-mail: ramesh.adige@ranbaxy.com
or
Raghu Kochar
Director — Corporate Communications
Ranbaxy Laboratories Ltd.
Plot 90, Sector 32, Gurgaon
Haryana122001, India
Tel: 91-124-4135141
Mobile: 9811617256
e-mail: raghu.kochar@ranbaxy.com
or
Krishnan Ramalingam
Sr.Manager — Corporate Communications
Plot 90, Sector 32, Gurgaon
Haryana122001, India
Tel: 91-124-4135143
Mobile: 9810042540
e-mail: krishnan.ramalingam@ranbaxy.com
Charles M. Caprariello
Vice President, Corporate Communications
Ranbaxy Inc.
(609) 720-5615
CONTACT: India: Ramesh L. Adige, Executive Director — Corporate Affairsand Global Corporate Communications, 91-124-4135000,, or Raghu Kochar, Director — CorporateCommunications, 91-124-4135141, or Mobile: 9811617256,, or Krishnan Ramalingam, Sr. Manager — CorporateCommunications, 91-124-4135143, or Mobile: 9810042540,, all of Ranbaxy Laboratories Ltd.; or USAContact: Charles M. gabapentin. Caprariello, Vice President, Corporate Communicationsof Ranbaxy Inc., 1-609-720-5615 ramesh.adige@ranbaxy.com raghu.kochar@ranbaxy.com krishnan.ramalingam@ranbaxy.com
Terms and conditions of use apply
Copyright 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
source
